Insulet Tumbles as UBS Slashes Omnipod Maker’s Price Target to $174

UBS downgraded Insulet Corp. (PODD) from Buy to Neutral on July 28, 2026.

The investment bank slashed its price target for the medical device company to $174.00. This adjustment represents a steep reduction from the previous $400.00 target.

UBS cited a cautious outlook for the manufacturer of the Omnipod Insulin Management System. The firm expects diminished performance potential for the stock over the near-to-medium term.